歌礼制药-B(01672)向美国FDA递交两项治疗肥胖症的IND申请：多肽胰淀素受体激动剂月注射剂ASC36以及ASC36联合多肽GLP-1R/GIPR激动剂ASC35的ASC36_35复方月注射剂

智通财经07-06

智通财经APP讯，歌礼制药-B(01672)发布公告，近期已向美国食品药品监督管理局 (FDA)递交了两项新药临床试验申请(IND)：每月一次至每季度一次新一代多肽胰淀素受体激动剂ASC36，以及ASC36_35 FDC，即ASC36联合多肽GLP-1R/GIPR 激动剂ASC35的每月一次注射复方制剂，用于治疗肥胖症。“Eloralintide联合替尔泊肽近期数据显示，在第32周时体重下降为...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohunote.com/m/news/2649614593?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2026-07-06 08:08","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2649614593","market":"sh","top_or_hot":-1,"title":"歌礼制药-B(01672)向美国FDA递交两项治疗肥胖症的IND申请：多肽胰淀素受体激动剂月注射剂ASC36以及ASC36联合多肽GLP-1R/GIPR激动剂ASC35的ASC36_35复方月注射剂","media":"智通财经","content":"<div>\n<p>智通财经APP讯，歌礼制药-B(01672)发布公告，近期已向美国食品药品监督管理局 (FDA)递交了两项新药临床试验申请(IND)：每月一次至每季度一次新一代多肽胰淀素受体激动剂ASC36，以及ASC36_35 FDC，即ASC36联合多肽GLP-1R/GIPR 激动剂ASC35的每月一次注射复方制剂，用于治疗肥胖症。“Eloralintide联合替尔泊肽近期数据显示，在第32周时体重下降为...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1463293.html\">网页链接</a>\n\n</div>\n","source":"stock_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>歌礼制药-B(01672)向美国FDA递交两项治疗肥胖症的IND申请：多肽胰淀素受体激动剂月注射剂ASC36以及ASC36联合多肽GLP-1R/GIPR激动剂ASC35的ASC36_35复方月注射剂</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n歌礼制药-B(01672)向美国FDA递交两项治疗肥胖症的IND申请：多肽胰淀素受体激动剂月注射剂ASC36以及ASC36联合多肽GLP-1R/GIPR激动剂ASC35的ASC36_35复方月注射剂\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-07-06 08:08 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.zhitongcaijing.com/content/detail/1463293.html><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经APP讯，歌礼制药-B(01672)发布公告，近期已向美国食品药品监督管理局 (FDA)递交了两项新药临床试验申请(IND)：每月一次至每季度一次新一代多肽胰淀素受体激动剂ASC36，以及ASC36_35 FDC，即ASC36联合多肽GLP-1R/GIPR 激动剂ASC35的每月一次注射复方制剂，用于治疗肥胖症。“Eloralintide联合替尔泊肽近期数据显示，在第32周时体重下降为...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1463293.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4160","symbol_name":"多样化房地产投资信托v","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/1463293.html","article_id":"2649614593","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2649614593","pubTimestamp":1783296500,"columns":[],"sourceInfo":{"source_id":"stock_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"智通财经APP讯，歌礼制药-B 发布公告，近期已向美国食品药品监督管理局 递交了两项新药临床试验申请：每月一次至每季度一次新一代多肽胰淀素受体激动剂ASC36，以及ASC36_35 FDC，即ASC36联合多肽GLP-1R/GIPR 激动剂ASC35的每月一次注射复方制剂，用于治疗肥胖症。临床前研究已确立了ASC36注射剂及ASC36_35 FDC复方注射剂的优越疗效。在ASC35 SALD月制剂近期取得的里程碑基础上，我们已递交ASC36月注射剂及 ASC36_35复方月注射剂两项IND。","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"BK4160":"多样化房地产投资信托v","JDOC":"JPMORGAN HEALTHCARE LEADERS ETF","IND":"Xtrackers Nifty 500 India ETF","BK4588":"碎股","BK1515":"抗疫概念","BK4590":"PTP","BK1191":"制药","BK1161":"生物科技","BK4585":"ETF&股票定投概念","01672":"歌礼制药-B","BK1574":"生物医药B类股","01477":"欧康维视生物-B","GIPR":"Generation Income Properties Inc.","GLP":"Global Partners Lp","LABU":"三倍做多标普生物-Direxion","BK4144":"石油与天然气的储存和运输"},"translate_title":"Ascletis-B (01672) submitted two IND applications to the US FDA for the treatment of obesity: polypeptide amylin receptor agonist monthly injection ASC36 and ASC36_35 compound monthly injection of ASC36 combined with polypeptide GLP-1R/GIPR agonist ASC35","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"LABU":1.5,"01477":1.5,"GIPR":1.5,"JDOC":1.5,"01672":1.5,"IND":1.5,"GLP":1.5},"content_text":"智通财经APP讯，歌礼制药-B(01672)发布公告，近期已向美国食品药品监督管理局 (FDA)递交了两项新药临床试验申请(IND)：每月一次至每季度一次新一代多肽胰淀素受体激动剂ASC36，以及ASC36_35 FDC，即ASC36联合多肽GLP-1R/GIPR 激动剂ASC35的每月一次注射复方制剂，用于治疗肥胖症。“Eloralintide联合替尔泊肽近期数据显示，在第32周时体重下降为29.0%。然而，该方案需要每周注射两针，一针eloralintide，另一针替尔泊肽。而有望成为同类首创、靶向胰淀素受体、GLP-1R和GIPR的皮下注射复方制剂ASC36_35 FDC，每月仅需注射一次，”歌礼创始人、董事会主席兼首席执行官吴劲梓博士表示，“同样令人振奋的是，在头对头饮食诱导肥胖(DIO)大鼠研究中，ASC36_35 FDC的减重效果较eloralintide联合替尔泊肽相对提升约51%。这些动物模型对人体疗效具有高度预测性。”ASC36和ASC35均是歌礼利用其基于结构的AI辅助药物发现(AISBDD)技术自主研发的。ASC36每月一次至每季度一次制剂以及ASC36_35 FDC每月一次复方制剂均为自组装脂质储库型(SALD)制剂，利用歌礼专有的超长效药物开发平台 (ULAP)技术开发而成。在头对头非人灵长类动物研究中，ASC36 SALD制剂的表观半衰期(observed half-life)约为eloralintide的6倍，支持在人体中每月一次至每季度一次皮下给药。在非人灵长类动物研究中，ASC36和ASC35两者在ASC36_35 FDC SALD制剂中均具有较长的表观半衰期，支持在人体中每月一次皮下给药。临床前研究已确立了ASC36注射剂及ASC36_35 FDC复方注射剂的优越疗效。在头对头DIO大鼠研究中(对人体疗效具有高度预测性)，靶向胰淀素受体的ASC36 单药较petrelintide单药和eloralintide单药的减重效果分别相对提升约91%和32%。在头对头DIO大鼠研究中，ASC36_35复方制剂靶向胰淀素受体、GLP-1R和GIPR 叁个靶点，减重效果较eloralintide联合替尔泊肽相对提升约51%。ASC36注射剂和ASC36_35 FDC复方注射剂具有优越的理化稳定性，在中性pH值附近没有纤维化导致的聚集沉淀。在ASC35 SALD月制剂近期取得的里程碑基础上，我们已递交ASC36月注射剂及 ASC36_35复方月注射剂两项IND。歌礼于该公告中宣布其每月一次皮下注射ASC35治疗肥胖症的I期临床试验已获美国FDA的IND批准，彰显了公司强劲的临床开发执行力及其ULAP技术的潜力。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2649614593","isCrawlerRequest":true}